FDA Approves Siponimod (Mayzent) for Multiple Sclerosis FDA Approves Siponimod (Mayzent) for Multiple Sclerosis

The agency has approved a new oral agent for relapsing forms of multiple sclerosis, including clinically isolated syndrome and secondary progressive disease.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news